With a string of new drugs for Alzheimer's disease making their way through late-stage clinical testing, the demand for suitable subjects to enrol into trials is running at an all-time high
A lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark health inequalities that have been brought into sharp focus by COVID-
Four years after being taken private, Parexel has been sold again, with Goldman Sachs' private equity arm and EQT paying $8.5 billion to claim ownership of the contract research organisatio
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
